No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract Panobinostat, lenalidomide, bortezomib, and dexamethasone was well-tolerated and showed potential in treating relapsed/refractory multiple myeloma

byKathleen Lau

February 25, 2021

in StudyGraphics

Higher SARS-CoV-2 infection rate in pregnant patients

RelatedReports

Lessons from real-world implementation of lung cancer screening

Chronic Disease

Guideline-based lymph node sampling is not associated with increased postoperative complications in lung cancer

June 9, 2026

Combined lenalidomide and rituximab dose escalation found to be safe for CLL

All Specialties

Venetoclax (Venclyxto) expands treatment options as chronic lymphocytic leukemia care moves further from chemotherapy

June 8, 2026

Quick Take: Effect of Pregabalin on Radiotherapy-Related Neuropathic Pain in Patients With Head and Neck Cancer: A Randomized Controlled Trial

Oncology

Why Pfizer Is Looking East for Its Next Generation of Cancer Drugs

June 4, 2026

Pharma

2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis

June 3, 2026

#VisualAbstract: Female sex may be associated with better overall and disease-specific survival in Merkel cell carcinoma

Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Transdermal estrogen shows similar cardiovascular safety profile to traditional luteinizing hormone therapy in patients with prostate cancer

#VisualAbstract Asciminib is shown to be safe and efficacious in clinical practice for treating patients with chronic myeloid leukemia

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports